Anxiolytic ¿-Carbolines

From Molecular Biology to the Clinic
Herausgegeben von Stephens, David N.

• Broschiertes Buch

Produktbeschreibung

Since the discovery some 15 years ago of benzodiazepinemodulatory sites associated with GABA A receptors, greateffort has gone into understanding their molecularpharmacology and into developing new anxiolytic drugs thatinteract selectively with them. Prominent in this researchhas beenthe discovery that ~-carbolines, a differentchemical class from benzodiazepines, also act at thesereceptors but that their effects are sometimes quitedifferent from those of the benzodiazepines.This bookdocuments the latest discoveries in the molecularbiology of the GABA A receptor and reveals howan integration of the results of research inmolecularbiology, synthetic chemistry, biochemical and behavioralpharmacology, and clinical pharmacology has paved the wayforthe development of ~-carbolines from substances inducinganxiety and convulsions to a novel therapy for anxietystates, achieving a behavioral selectivity through selectiveactions at subtypes of receptors.

Produktdetails

• Psychopharmacology Series .11
• Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
• Artikelnr. des Verlages: 978-3-642-78453-8
• 1993
• Seitenzahl: 168
• Erscheinungstermin: 8. Dezember 2011
• Englisch
• Abmessung: 235mm x 155mm x 10mm
• Gewicht: 265g
• ISBN-13: 9783642784538
• ISBN-10: 3642784534
• Artikelnr.: 36122277

Inhaltsangabe

Discovery of ?-Carboline Ligands for Benzodiazepine Receptors.- ?-Carboline-3-Carboxylic Acid Ethyl Ester: A Lead for New Psychotropic Drugs.- Molecular Biology of Gamma-Aminobutyric Acid Type A/Benzodiazepine Receptors.- Immunohistochemical Mapping of Gamma-Aminobutyric Acid Type A Receptor Alpha Subunits in Rat Central Nervous System.- Abecarnil is a Full Agonist at Some and a Partial Agonist at Other Recombinant Gamma-Aminobutyric Acid Type A Receptor Subtypes.- Pharmacological Evidence for Full Agonist Activity of Abecarnil at Certain Receptors.- Abecarnil: A Novel Anxiolytic with Mixed Full Agonist/Partial Agonist Properties in Animal Models of Anxiety and Sedation.- Abecarnil Shows Reduced Tolerance Development and Dependence Potential in Comparison to Diazepam.- Behavioral Pharmacology of Abecarnil in Baboons: Reduced Dependence and Abuse Potential.- Abecarnil Used to Treat Benzodiazepine Withdrawal.- Abecarnil, A New ?-Carboline Anxiolytic: Preliminary Clinical Pharmacology.